OR WAIT null SECS
February 21, 2019
Mustang intends to combine an oncolytic virus with an interleukin-13 Rα2-(IL13Rα2)-specific chimeric antigen receptor to potentially enhance efficacy in treating glioblastoma multiforme.
Teva will apply Insilico’s technology for predictive biomanufacturing to create more efficient biomanufacturing processes.
India’s Bharat Biotech is set to acquire GlaxoSmithKline’s Chiron Behring Vaccines, a World Health Organization-prequalified global manufacturer of rabies vaccines.
February 20, 2019
The company will invest an additional $60 million to expand its manufacturing facility in Durham County, NC.
February 19, 2019
The acquisition would strengthen Charles River’s contract research capabilities.
In a deal worth $530 million, the companies will develop and commercialize an anti-epileptic drug candidate in Europe.
February 15, 2019
The partners will collaborate on the development and commercialization of a B-cell maturation antigen-targeting immunotherapeutic for treating multiple myeloma.
February 14, 2019
CatSci has announced an expansion of its offering to include end-to-end services with an additional focus on lead optimization.
Pathios Therapeutics and Sygnature Discovery have signed a strategic and innovative partnership agreement aimed at accelerating Pathios’ drug discovery and development programs.
The multi-year agreement will give Novartis access to AbCellera’s expertise and state-of-the-art antibody discovery technology for up to ten clinically-relevant disease targets.